natgillin/translations-raw huggingface dataset:
Duration of treatment – Treatment-naïve adults and prior treatment relapsers
Trajanje liječenja – Odrasli bolesnici koji prethodno nisu bili liječeni i bolesnici s relapsom nakon prethodnog liječenja
Duration of treatment –dual therapy with Pegasys and ribavirin
Trajanje liječenja– dvojna terapija lijekom Pegasys i ribavirinom
Duration of treatment–dual therapy with Pegasys and ribavirin
Trajanje liječenja– dvojna terapija lijekom Pegasys i ribavirinom
Duration of tumour & symptomatic response (days) - independent review; median (min, max)
Trajanje tumora i simptomatski odgovor (dani) - nezavisna procjena; medijan (minimum, maksimum)
Duration PD [yrs (SD)]
Trajanje PD [godina (SD)]
During 12 months’ monotherapy treatment with LUMIGAN 0.3 mg/ml in adults, versus timolol, mean change from baseline in morning (08:00) intraocular pressure ranged from -7.9 to -8.8 mm Hg.
Tijekom 12-mjesečnog ispitivanja monoterapije s LUMIGAN-om 0,3 mg/ml u odraslih bolesnika, u usporedbi s timololom, prosječna promjena u odnosu na početnu vrijednost u jutarnjem (08:00) intraokularnom tlaku kretala se u rasponu od 7,9 do 8,8 mm Hg.
During 24 hours following administration of a single radiolabelled [3H]­liraglutide dose to healthy subjects, the major component in plasma was intact liraglutide.
Tijekom 24 sata od primjene jedne doze radioaktivno obilježenog 3H-liraglutida u zdravih ispitanika glavna sastavnica u plazmi bio je nepromijenjeni liraglutid.
During 52 weeks of studies UC-I and UC-II, lower rates of all-cause hospitalisations and UC-related hospitalisations were observed for the adalimumab-treated arm compared to the placebo.
Tijekom 52 tjedna ispitivanja UC-I i UC-II, zamijećene su niže stope hospitalizacija zbog bilo kojeg uzroka i hospitalizacija povezanih s UC-om u skupini liječenoj adalimumabom u odnosu na skupinu koja je primala placebo.
During a 4-week cycle of treatment
Tijekom 4-tjednog ciklusa liječenja
During a cumulative review of severe skin reaction events, three cases of Stevens-Johnson syndrome (SJS) were identified where a causal association is assessed as at least possible including two reports with reasonable time to onset and biopsy confirmed.
Tijekom pregleda kumulativnih podataka o pojavi teških kožnih reakcija utvrđena su tri slučaja Stevens-Johnsonovog sindroma (SJS) gdje je uzročno-posljedična povezanost procijenjena barem kao moguća, s time da je u dva prijavljena slučaja sindrom nastupio unutar razdoblja koje se može povezati s primjenom lijeka i bio potvrđen biopsijom.
During a flu pandemic, Ebilfumin can also be used to treat or prevent flu in babies below one year of age.
Tijekom pandemije gripe Ebilfumin se može također koristiti za sprječavanje gripe u dojenčadi mlađe od godine dana.
During a flu pandemic, Tamiflu can also be used to prevent flu in babies below one year of age.
Tijekom pandemije gripe, Tamiflu se može također koristiti za sprječavanje gripe u dojenčadi mlađe od godine dana.
During a pandemic situation, the frequency of submission of periodic safety update reports specified in Article 24 of Regulation (EC) No 726/2004 will not be adequate for the safety monitoring of a pandemic vaccine for which high levels of exposure are expected within a short period of time.
726/2004 neće biti dostatna za sigurnosno praćenje pandemijskog cjepiva kod kojeg se očekuje visoka razina izloženosti u kratkom vremenskom razdoblju.
During a pandemic situation, the frequency of submission of periodic safety update reports specified in Article 24 of Regulation (EC) No 726/2004 will not be adequate for the safety monitoring of a pandemic vaccine for which high levels of exposure are expected within a short period of time.
Tijekom pandemijske situacije, učestalost podnošenja periodičkih izvješća o neškodljivosti lijeka predviđena člankom 24 Uredbe (EK) br.726/2004 neće biti primjerena za praćenje sigurnosti pandemijskog cjepiva za koje se očekuju visoke razine izlaganja u kratkom roku.
During a pandemic situation, the frequency of submission of periodic safety update reports specified in Article 24 of Regulation 726/2004/EC will not be adequate for the safety monitoring of a pandemic vaccine for which high levels of exposure are expected within a short period of time.
Tijekom pandemijske situacije, učestalost podnošenja periodičkih izvješća o neškodljivosti lijeka predviđena člankom 24 Uredbe 726/2004/EK neće biti primjerena za praćenje sigurnosti pandemijskog cjepiva za koje se očekuju visoke razine izlaganja u kratkom roku.
During a pandemic situation, the resources must be concentrated on a timely and effective monitoring of the safety profile of the influenza vaccines used during the pandemic.
Tijekom pandemijske situacije resursi se moraju usmjeriti na pravovremeno i učinkovito praćenje sigurnosnog profila cjepiva protiv gripe korištenih tijekom pandemije.
During a pandemic situation, the resources must be concentrated on a timely and effective monitoring of the safety profile of the influenza vaccines used during the pandemic.
Tijekom pandemijske situacije, resursi se moraju koncentrirati na pravovremen i učinkovit nadzor sigurnosnog profila cjepiva protiv influence koja se koriste tijekom pandemije.
During a pandemic, the virus strain in Foclivia will have to be replaced by the strain causing the pandemic before the vaccine can be used.
Tijekom pandemije soj virusa u cjepivu Foclivia morat će se zamijeniti sojem koji uzrokuje pandemiju prije nego se cjepivo bude moglo koristiti.
During a pandemic, the virus strain in Pandemic Influenza Vaccine H5N1 Baxter AG will have to be replaced by the strain causing the pandemic before the vaccine can be used.
Tijekom pandemije, soj virusa u cjepivu protiv pandemijske influence H5N1 Baxter AG morat će se zamijeniti sojem koji uzrokuje pandemiju prije nego što se cjepivo može koristiti.
During a pharmacokinetic study with Imiquimod 3.75% cream following application of 2 sachets once daily (18.75 mg imiquimod/day) for up to three weeks to the entire face and/or scalp (approximately 200 cm2), low systemic absorption of imiquimod was observed in patients with AK.
Tijekom farmakokinetičkog ispitivanja s imikvimod 3,75 % kremom nakon primjene 2 vrećice jedanput dnevno (18,75 mg imikvimoda/dan) tijekom do tri tjedna na cijelo lice i/ili tjeme (približno 200 cm2), opažena je niska sistemska apsorpcija imikvimoda u bolesnika s AK-om.
During a randomised withdrawal period, significantly more patients re-randomised to placebo experienced disease relapse (loss of PASI 75 response) compared with patients re-randomised to Enbrel.
Tijekom randomiziranog razdoblja prekida terapije, znatno više bolesnika koji su ponovno randomizirani u skupinu s placebom ušlo je u recidiv bolesti (gubitak odgovora PASI 75) u usporedbi s bolesnicima koji su ponovno randomizirani u skupinu s Enbrelom.
During a refill procedure, a very small amount of insulin may be deposited subcutaneously, possibly resulting in hypoglycaemia.
Za vrijeme nadopunjavanja pumpe vrlo mala količina inzulina može se supkutano unijeti u organizam, što može dovesti do hipoglikemije.
During a refill procedure, a very small amount of Insuman Implantable may be deposited subcutaneously, which might result in low blood sugar levels.
Za vrijeme nadopunjavanja vrlo mala količina lijeka Insuman Implantable može dospjeti pod kožu, što može dovesti do niskih razina šećera u krvi.
During a treatment cycle for those toxicities considered by the treating physician not to be related to capecitabine, capecitabine should be continued and the dose of the other medicinal product should be adjusted according to the appropriate Prescribing Information.
Ako se tijekom liječenja razviju toksične reakcije, koje prema mišljenju liječnika koji provodi liječenje nisu povezane s primjenom kapecitabina, liječenje kapecitabinom treba nastaviti, a dozu drugog lijeka treba prilagoditi prema Sažetku opisa svojstava tog lijeka.
During administration of micafungin, anaphylactic/anaphylactoid reactions including shock may occur.
Tijekom primjene mikafungina mogu nastati anafilaktičke/anafilaktoidne reakcije, uključujući i šok.
During an 8-week baseline period, patients had to experience 4 partial onset seizures per 28 days.
Tijekom početnog razdoblja u trajanju od 8 tjedana, bolesnici su morali imati 4 ili više parcijalnih napadaja tijekom 28 dana.
During an accumulated exposure of more than 54,000 days (corresponding to 342 patient years), no factor VIII inhibitor development was observed in the phase 3a clinical trials in previously treated patients.
Tijekom kumulativne izloženosti od preko 54 000 dana (što odgovara 342 bolesnik-godine), u kliničkim ispitivanjima faze 3a nije primijećen razvoj inhibitora faktora VIII u prethodno liječenih bolesnika.
During an embryo-fetal development study where siltuximab was administered intravenously to pregnant cynomolgus monkeys (gestation day 20 – 118) at doses of 9.2 and 46 mg/kg/week, no maternal or fetal toxicity was observed.
Tijekom ispitivanja embrio-fetalnog razvoja, u kojem je siltuksimab bio intravenski primijenjen skotnim cynomolgus majmunima (gestacijski dan 20 – 118) pri dozama od 9,2 i 46 mg/kg/tjedan nije opažena maternalna ili fetalna toksičnost.
During an open-label extension period the percentage of patients meeting the composite stability endpoint was maintained at 87.4% after 24 months of treatment with Cerdelga.
Tijekom otvorenog produžetka ispitivanja postotak bolesnika koji su postigli kompozitni ishod stabilnosti održan je na 87,4% nakon 24 mjeseca liječenja lijekom Cerdelga.
During an open-label extension period, patients who continued to receive Cerdelga (n=18) showed further improvements (change from baseline) in haemoglobin level (1.02 g/dL), platelet count (58.16%) and spleen and liver volumes (-44.61% and -11.18% respectively) after 18 months of treatment.
U otvorenom produžetku ispitivanja, bolesnici koji su nastavili primati lijek Cerdelga (n=18) pokazali su daljnja poboljšanja (promjenu od početnih vrijednosti) razine hemoglobina (1,02 g/dl), broja trombocita (58,16%) i volumena slezene i jetre (-44,61% odnosno -11,18%) nakon 18 mjeseci liječenja.
During an operation on the eye for cloudiness of the lens (cataract), the iris (the coloured part of the eye) may become floppy during surgery (known as “floppy iris syndrome”) that may lead to eye damage. are aware of having dangerously low numbers of a certain type of white blood cell needed to fight infection in your blood
Tijekom operacije na oku za zamućenje leće (katarakta), šarenica (obojeni dio oka) može postati mekana tijekom operacije (poznato kao „sindrom mekane šarenice“) što može dovesti do oštećenja oka. ste svijesni da imate opasno nizak broj određne vrste bijelih krvnih stanica koja je potrebna za borbu protv infekcije.
during an operation, to stop bleeding and to seal the surfaces of internal organs;
tijekom operacije, kako bi zaustavilo krvarenje i zatvorile površine unutarnjih organa.
During and after Simponi treatment
Tijekom i nakon liječenja lijekom Simponi
During and after Simponi treatment:
Tijekom i nakon liječenja lijekom Simponi:
During and after treatment with Zalmoxis the physician must be aware of acute and chronic sign and symptoms of GvHD at any time and ensure that either ganciclovir or valganciclovir is available at ward for early treatment of GvHD.
Tijekom i nakon liječenja lijekom Zalmoxis, liječnici u svakom trenutku moraju paziti na akutne i kronične znakove i simptome GvHD-a te osigurati dostupnost bilo ganciklovira ili valganciklovira na bolničkom odjelu radi ranog liječenja GvHD-a.
During antipsychotic treatment, improvement in the patient’s clinical condition may take several days to some weeks.
Tijekom liječenja psihoze potrebno je pričekati nekoliko dana do nekoliko tjedana od početka liječenja da bi došlo do poboljšanja kliničkog stanja bolesnika.
During antiviral therapy, the aim of treatment should be to keep platelet counts at a level that prevents the risk of bleeding complications, normally around 50,000-75,000/µl.
Tijekom antivirusnog liječenja, cilj liječenja treba biti održavanje broja trombocita na razini koja sprječava rizik od komplikacija krvarenja, koja je normalno oko 50 000-75 000/ µl.
During bisphosphonate treatment patients should be advised to report any thigh, hip or groin pain and any patient presenting with such symptoms should be evaluated for an incomplete femur fracture.
Bolesnicima treba savjetovati da tijekom liječenja bisfosfonatima prijave svaki bol u natkoljenici, kuku ili preponama i svakog bolesnika s takvim simptomima treba pregledati na nepotpuni prijelom bedrene kosti.
During bisphosphonate treatment patients should be advised to report any thigh, hip or groin pain and any patient presenting with such symptoms should be evaluated for an incomplete femur fracture.
Bolesnicima treba savjetovati da tijekom liječenja bisfosfonatima prijave svaku bol u bedru, kuku ili preponama a svakog bolesnika s takvim simptomima treba pregledati na nepotpuni prijelom bedrene kosti.
During bisphosphonate treatment patients should be advised to report any thigh, hip or groin pain and any patient presenting with such symptoms should be evaluated for an incomplete femur fracture.
Tijekom liječenja bisfosfonatima, bolesnike treba uputiti da prijave bol u bedru, kuku ili preponi te svakoga bolesnika s ovim simptomima treba pregledati ne bi li se otkrio nepotpuni lom bedrene kosti.
During bisphosphonate treatment, all patients should be encouraged to maintain good oral hygiene, receive routine dental check-ups, and report any oral symptoms such as dental mobility, pain, or swelling.
Tijekom liječenja bisfosfonatima, sve se bolesnice mora poticati da održavaju dobru oralnu higijenu, redovito posjećuju stomatologa i prijave bilo koji oralni simptom kao što je pomičnost zuba, bolovi ili oticanje.
During breast feeding.
Tijekom dojenja.
During cataract surgery, a condition called intraoperative floppy iris syndrome (IFIS) can happen if you take or have taken INVEGA.
Tijekom operacije katarakte, može doći do stanja oka nazvanog intraoperacijski sindrom meke šarenice (IFIS) ukoliko uzimate ili ste uzimali XEPLION.
During cataract surgery, a condition called intraoperative floppy iris syndrome (IFIS) can happen if you take or have taken Xeplion.
Tijekom operacije katarakte, može doći do stanja oka nazvanog intraoperacijski sindrom meke šarenice (IFIS) ukoliko uzimate ili ste uzimali Xeplion.
During clinical development of Ilaris in over 2,300 patients, no anaphylactoid or anaphylactic reactions were reported.
Tijekom kliničkog razvoja Ilarisa, kod više od 2300 bolesnika nisu bile zabilježene anafilaktoidne ili anafilaktičke reakcije.
During clinical field trials, no interactions between Simparica chewable tablets for dogs and routinely used veterinary medicinal products were observed.
Tijekom kliničkih terenskih ispitivanja nisu primijećene interakcije između Simparica tableta za žvakanje za pse i redovito upotrijebljenog veterinarsko – medicinskog proizvoda.
During clinical studies 183 cancer patients and 96 healthy volunteers were exposed to Nivestim.
Tijekom kliničkih ispitivanja je 183 bolesnika s rakom i 96 zdravih dobrovoljaca bilo izloženo Nivestimu.
During clinical studies 541 cancer patients and 188 healthy volunteers were exposed to Ratiograstim.
U kliničkim je ispitivanjima Ratiograstim primao 541 onkološki bolesnik i 188 zdravih dobrovoljaca.
During clinical studies 541 cancer patients and 188 healthy volunteers were exposed to Tevagrastim.
U kliničkim je ispitivanjima Tevagrastim primao 541 onkološki bolesnik i 188 zdravih dobrovoljaca.
During clinical studies maropitant plasma levels conferred efficacy from 1 hour after administration.
Tijekom kliničkih ispitivanja razine maropitanta u plazmi odgovaraju efikasnosti od 1 sat nakon davanja.
During clinical studies maropitant plasma levels conferred efficacy from 1 hour after administration..
Tijekom kliničkih ispitivanja razine maropitanta u plazmi odgovaraju učinkovitosti od 1 sat nakon davanja.
During clinical studies of Cayston, isolation of MRSA did not result in worsening of lung function.
Tijekom kliničkih ispitivanja Caystona izolacija MRSA-e nije rezultirala pogoršanjem plućne funkcije.
During clinical studies with CEPROTIN, a total of 6 non-serious adverse drug reactions (ADRs) were reported in 3 of 225 patients enrolled.
Tijekom kliničkih ispitivanja lijeka CEPROTIN prijavljeno je ukupno 6 blagih nuspojava (ADR-ova) u 3 od 225 uključenih pacijenata.
During clinical studies with Nuwiq in previously treated paediatric (2 to 11 years, n = 58), adolescent (12 to 17 years, n = 3) and adult patients (n = 74) with severe haemophilia A, a total of 8 adverse drug reactions (ADRs) (6 in adults, 2 in children) were reported in 5 patients (3 adults, 2 children).
Tijekom kliničkih ispitivanja lijeka Nuwiq na prethodno liječenim pedijatrijskim bolesnicima (2-11 godina, n = 58), adolescentima (12-17 godina, n = 3) i odraslim bolesnicima (n = 74) s teškom hemofilijom A, prijavljeno je ukupno 8 nuspojava na lijek (6 u odraslih, 2 u djece) u 5 bolesnika (3 odrasla, 2 djece).
During clinical studies, blood samples from patients with Dupuytren’s contracture and Peyronie’s disease were tested at multiple time points for antibodies to the protein components of the medicinal product (AUX-I and AUX-II).
Tijekom kliničkih ispitivanja, uzorci krvi bolesnika s Dupuytrenovom kontrakturom i Peyronijevom bolešću bili su testirani na protutijela na proteinske sastavnice ovog lijeka (AUX-I i AUX-II) više puta.
During clinical studies, episodes of headache and insomnia have been reported (7.7 % to 8.4%).
Tijekom kliničkih ispitivanja, zabilježene su epizode glavobolje i nesanice (7,7 % do 8,4 %).
During clinical studies, more patients on Ultibro Breezhaler experienced clinically notable changes in blood glucose (4.1%) at the recommended dose than on placebo (2.3%).
Tijekom kliničkih ispitivanja, više je bolesnika koji su koristili Ultibro Breezhaler imalo klinički značajne promjene glukoze u krvi (4.1%) u preporučenoj dozi nego pri primjeni placeba (2.3%).
During clinical studies, more patients on Ulunar Breezhaler experienced clinically notable changes in blood glucose (4.1%) at the recommended dose than on placebo (2.3%).
Tijekom kliničkih ispitivanja, više je bolesnika koji su koristili Ulunar Breezhaler imalo klinički značajne promjene glukoze u krvi (4.1%) u preporučenoj dozi nego pri primjeni placeba (2.3%).
During clinical studies, more patients on Xoterna Breezhaler experienced clinically notable changes in blood glucose (4.1%) at the recommended dose than on placebo (2.3%).
Tijekom kliničkih ispitivanja, više je bolesnika koji su koristili Xoterna Breezhaler imalo klinički značajne promjene glukoze u krvi (4.1%) u preporučenoj dozi nego pri primjeni placeba (2.3%).
During clinical trials and after the vaccine came on the market, the following side effects were reported with the use of IDflu.
Kod primjene IDflu-a u kliničkim ispitivanjima i praćenjem nakon stavljanja cjepiva na tržište zabilježene su dolje navedene nuspojave.
During clinical trials in adult and adolescent patients 12 years of age and older, the most commonly reported adverse reactions were headaches and injection site reactions, including injection site pain, swelling, erythema and pruritus.
Tijekom kliničkih ispitivanja u odraslih bolesnika i adolescenata 12 godina starosti i više, najčešće zabilježene nuspojave bile su glavobolje i reakcije na mjestu injiciranja, uključujući bol na mjestu injiciranja, oteklinu, eritem, svrbež.
During clinical trials with Iblias in approximately 200 paediatric and adult patients diagnosed with severe haemophilia A (FVIII < 1%) with previous exposure to factor VIII concentrates ≥ 50 ED, no case of inhibitor occurred.
Tijekom kliničkih ispitivanja s lijekom Iblias u otprilike 200 pedijatrijskih i odraslih bolesnika kojima je dijagnosticirana teška hemofilija A (FVIII < 1%) s prethodnom izloženošću koncentratima faktora VIII ≥ 50 dana izloženosti nije došlo do pojave inhibitora.
During clinical trials with Ilaris in CAPS patients mean values for haemoglobin increased and those for white blood cell, neutrophils and platelets decreased.
Tijekom kliničkih ispitivanja s Ilarisom kod bolesnika s CAPS-om srednje vrijednosti hemoglobina su se povisile, a leukocita, neutrofila i trombocita su se snizile.
During clinical trials with Kovaltry in approximately 200 paediatric and adult patients diagnosed with severe haemophilia A (FVIII < 1 %) with previous exposure to factor VIII concentrates ≥ 50 ED, no case of inhibitor occurred.
Tijekom kliničkih ispitivanja s lijekom Kovaltry u otprilike 200 pedijatrijskih i odraslih bolesnika kojima je dijagnosticirana teška hemofilija A (FVIII < 1%) s prethodnom izloženošću koncentratima faktora VIII ≥ 50 dana izloženosti nije došlo do pojave inhibitora.
During clinical trials with Kovaltry in approximately 200 paediatric and adult patients diagnosed with severe haemophilia A (FVIII < 1%) with previous exposure to factor VIII concentrates ≥ 50 ED, no case of inhibitor occurred.
Tijekom kliničkih ispitivanja s lijekom Kovaltry u otprilike 200 pedijatrijskih i odraslih bolesnika kojima je dijagnosticirana teška hemofilija A (FVIII < 1%) s prethodnom izloženošću koncentratima faktora VIII ≥ 50 dana izloženosti nije došlo do pojave inhibitora.
During clinical trials with Nonafact conducted in previously treated patients development of inhibitors was not reported.
Tijekom kliničkih pokusa s lijekom Nonafact na ranije liječenim pacijentima nije opisan razvoj inhibitora.
During clinical trials with Suprelorin 4.7 mg, the mean duration of testosterone suppression was 1.5 times longer among smaller size dogs (<10 kg) compared with all larger dogs.
Tjekom kliničkih ispitivanja sa Superlorinom 4,7 mg srednje vrijeme supresije testosterona bilo je 1,5 puta dulje u manjih pasa (<10 kg) u usporedbi sa većim psima.
During clinical trials, most of the smaller size dogs (<10 kg) maintained suppressed levels of testosterone for more than 12 months following implantation.
Tijekom kliničkih ispitivanja, većina manjih pasa (< 10 kg) održali su nižu razinu testosterona duže od 12 mjeseci nakon implantacije.
During clinical trials, pain on injection and injection site swellings were seen very commonly in treated pigs.
Tijekom kliničkih ispitivanja, u tretiranih svinja često su se vidjeli bol i otekline.
During clinical trials, patients who failed to show a virologic response after 6 months of treatment (HCV-RNA below lower limit of detection) did not become sustained virologic responders (HCV- RNA below lower limit of detection six months after withdrawal of treatment).
Bolesnici koji u kliničkim ispitivanjima nisu pokazali virološki odgovor (HCV-RNK ispod donje granice mjerljivosti) nakon 6 mjeseci liječenja, nisu razvili trajan virološki odgovor (HCV-RNK ispod donje granice mjerljivosti 6 mjeseci nakon prestanka liječenja).
During clinical trials, the most frequently reported adverse reactions were nausea/vomiting (73%), leucopoenia (70%), alopecia (66%), neutropenia (46%), asthenia/fatigue (46%), stomatitis/mucositis (42%), thrombocytopenia (31%) and anaemia (30%).
Tijekom kliničkih ispitivanja najčešće prijavljene nuspojave bile su mučnina/povraćanje (73%), leukopenija (70%), alopecija (66%), neutropenija (46%), astenija/umor (46%), stomatitis/mukozitis (42%), trombocitopenija (31%) i anemija (30%).
during clinical trials† and ‡
ispitivanjima† i
During combination therapy for up to 48 weeks with interferon alfa- 2b and ribavirin, growth inhibition was observed that resulted in reduced final adult height in some patients.
Za vrijeme kombinirane terapije interferonom alfa-2b i ribavirinom u trajanju do 48 tjedana primijećen je zastoj u rastu koji je u nekih bolesnika rezultirao smanjenom konačnom visinom u odrasloj dobi.
During combination therapy for up to 48 weeks with interferon alfa- 2b and ribavirin, growth inhibition was observed that resulted in reduced final adult height in some patients.
Za vrijeme kombinirane terapije interferonom alfa-2b i ribavirinom u trajanju do 48 tjedana primijećen je zastoj u rastu koji je u nekih bolesnika rezultirao smanjenom konačnom visinom u odrasloj dobi..